Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.50 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401455 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL30477937 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL29398070 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL30252212 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL119402 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL2366569 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL2366563 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL1738651 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL2367241 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A | |
| SCHEMBL12055781 | 1.00 | CASP3 (0.50) | CASP3MDM4TP53PIN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025098391-A9 | SELECTIVE DRUG RELEASE FROM CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | NONA BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2026-04-30 | — | — | WO | disclosed |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| WO-2025098391-A1 | SELECTIVE DRUG RELEASE FROM CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | NONA BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2025-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | ERBB2, EGFR, ERBB3 | CASP3 1904/4885MDM4 2510/4885TP53 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.